Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.

ABSTRACT:

Unlabelled

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. The clinical heterogeneity of HCC, and the lack of good diagnostic markers and treatment strategies, has rendered the disease a major challenge. Patients with HCC have a highly variable clinical course, indicating that HCC comprises several biologically distinctive subgroups reflecting a molecular heterogeneity of the tumors. Transforming growth factor beta (TGF-beta) is known to exhibit tumor stage dependent suppressive (that is, growth inhibition) and oncogenic (that is, invasiveness) properties. Here, we asked if a TGF-beta specific gene expression signature could refine the classification and prognostic predictions for HCC patients. Applying a comparative functional genomics approach we de

SUBMITTER: Coulouarn C 

PROVIDER: S-EPMC2762280 | biostudies-literature | 2008 Jun

REPOSITORIES: biostudies-literature